OncoAlert and ecancer weekly roundup for August 1-8 2020

PARP inhibitors and prostate cancer: A new era of precision medicine

Oncology pharmacist perspective on PARP inhibitors for castration-resistant prostate cancer

The role of PARP-2 in inhibiting prostate cancer

KEYNOTE-427 updates: First-line pembrolizumab monotherapy in patients with advanced clear cell renal cell carcinoma

Association of gene expression with clinical outcomes in RCC patients treated with pembrolizumab

Renal cell cancer: Highlights from ASCO 2020

FRACTION-RCC: Evaluating nivolumab plus ipilimumab in patients with treatment-refractory advanced renal cell carcinoma

HERO: Relugolix versus leuprolide acetate for advanced prostate cancer

The future of PARP inhibitors in prostate cancer

IMvigor130: Atezolizumab with or without chemotherapy in metastatic urothelial cancer

CTC count as a prognostic marker for androgen deprivation plus orteronel or bicalutamide in mCSPC